Biohaven is a biopharmaceutical company that discovers, develops, and commercializes therapies in immunology, neuroscience, and oncology. The company's pipeline focuses on three strategic platforms: Kv7 ion channel activators for neurological disorders, protein degraders targeting immunological diseases, and myostatin inhibitors for neuromuscular and metabolic conditions. Biohaven plans to commercialize its lead programs in the United States through a specialty sales force while retaining worldwide rights to substantially all candidates, with manufacturing outsourced to third-party contractors, and competes with major pharmaceutical companies on the basis of drug safety, efficacy, pricing, and reimbursement access.